Oxygen Of The Saccharide Radical Bonded Directly To A Polycyclo Ring System Of Three Or More Carbocyclic Rings Patents (Class 514/33)
  • Publication number: 20130324399
    Abstract: Compositions and methods for protecting plants from fungal, bacterial, and viral diseases are provided, which compositions comprise at least one compound that produces systemic acquired resistance and at least one antifungal compound. Compositions of the disclosure may be applied directly to seeds, seedlings, shoots, roots, and/or foliage of the plant to be protected, thereby protecting them from the fungal, bacterial, and viral diseases.
    Type: Application
    Filed: August 9, 2011
    Publication date: December 5, 2013
    Applicant: Bayer Cropscience LP
    Inventors: Jennifer Riggs, Danise Beadle, Katharine Vuocolo
  • Patent number: 8569250
    Abstract: A method of inhibiting dipeptidyl peptidase-IV comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of formulae (I A), (I B), (X A), (X B), (Y A) or (Y or B), wherein R? represents and R? represents hydrogen, hydroxy, C1-C7alkoxy, C1-C8-alkanoyloxy, or R5R4N—CO—O—, where R4 and R5 independently are C1-C7alkyl or phenyl which is unsubstituted or substituted by a substitutent selected from C1-C7alkyl, C1-C7alkoxy, halogen and trifluoromethyl and where R4 additionally is hydrogen; or R4 and R5 together represent C3-C6alkylene, in free form or in form of a pharmaceutically acceptable acid addition salt.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: October 29, 2013
    Assignee: Novartis AG
    Inventors: Ulrich Hassiepen, Matthias Kittelmann
  • Patent number: 8557784
    Abstract: The present invention provides a pharmaceutically acceptable compound, a pharmaceutical composition comprising the above-mentioned pharmaceutically acceptable compound. The pharmaceutically acceptable compound provided by the present invention is a salt of a basic group-containing morphinan derivative and a carboxyl group-containing glycyrrhizinic acid and has the ability to be used to manufacture medicaments for treating and/or preventing cough, ameliorating pains, treating respiratory system diseases, treating cardiovascular diseases and treating liver diseases.
    Type: Grant
    Filed: July 7, 2011
    Date of Patent: October 15, 2013
    Assignee: Standard Chem. & Pharm. Co., Ltd.
    Inventors: Chin-Tsai Fan, Cheng-Shun Lai, Wen-Yen Yeh, Yu-Ying Liu
  • Patent number: 8530435
    Abstract: Provided are formulations containing brassinosteroids or their derivatives for treating androgen-associated conditions, such as prostate problems. Particularly formulations comprising at least one brassinosteroid or a derivative thereof are provided for treating benign prostatic hyperplasia or androgenic alopecia.
    Type: Grant
    Filed: June 2, 2011
    Date of Patent: September 10, 2013
    Assignee: Grasses of Eden Ltd.
    Inventors: Amir Kitron, Rochel Pergamentz
  • Patent number: 8530433
    Abstract: The present invention provides the use of icariside II or extract comprising thereof in manufacture of products for preventing or treating male or female sexual dysfunction, in particular, the use for improving pathological or organical changes in erectile tissues of patients with erectile dysfunction.
    Type: Grant
    Filed: June 12, 2009
    Date of Patent: September 10, 2013
    Assignee: Bjo-Biomed Ltd
    Inventors: Zhongcheng Xin, Hua Xin, Zhenji Tian
  • Publication number: 20130225517
    Abstract: The invention provides compounds of formula I: or salts thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I and therapeutic methods for treating cancer.
    Type: Application
    Filed: February 22, 2013
    Publication date: August 29, 2013
    Applicant: University of Iowa Research Foundation
    Inventor: University of Iowa Research Foundation
  • Patent number: 8518898
    Abstract: Disclosed is a cytoprotective composition comprising hesperidin or a pharmaceutically acceptable salt thereof as an active ingredient. Having the ability to protect cells from radiation-induced injuries in addition to being non-toxic to cells, hesperidin in accordance with the present invention can be used as an active cytoprotective agent.
    Type: Grant
    Filed: September 11, 2008
    Date of Patent: August 27, 2013
    Assignee: Korea Atomic Energy Research Institute
    Inventors: Sang Hyun Park, Kannampalli Pradeep, Kyong Cheol Ko
  • Publication number: 20130171283
    Abstract: Disclosed is a composition, and method for its use, that includes any one of, any combination of, or all of Centella asiactica, Vitis vinifera seed, Magnolia bark, Camellia sinensis, and/or dihydroxymethylchromone. The composition can be used to treat telangiectasia.
    Type: Application
    Filed: December 10, 2012
    Publication date: July 4, 2013
    Applicant: MARY KAY INC.
    Inventor: Mary Kay Inc.
  • Patent number: 8470980
    Abstract: The present invention relates to, inter alia, extracellular drug conjugates (EDC) in which an antibody or other targeting agent (e.g. a targeting moiety) is linked to a drug through a linker (e.g. a non-cleavable linker). These conjugates are useful in the treatment of disease and/or as a tool in the evaluation of biological systems.
    Type: Grant
    Filed: September 9, 2010
    Date of Patent: June 25, 2013
    Assignee: Centrose, LLC
    Inventors: James R. Prudent, Jon S. Thorson, Jill Hutchinson Bollettieri
  • Publication number: 20130157967
    Abstract: The invention described herein relates to the use of an aqueous composition containing at least one phospholipid. at least one glycyrrhizic acid or salts of glycyrrhizic acid for the manufacture of mediciments for the removal of subcutaneous fat accumulation.
    Type: Application
    Filed: April 28, 2011
    Publication date: June 20, 2013
    Applicant: LICHTBLICK GMBH
    Inventors: Karl-Josef Gundermann, Dirk Brandl
  • Publication number: 20130150317
    Abstract: A composition comprising mithramycin or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of renal cell carcinoma. In particular, the composition is suitable for use in the treatment of clear cell renal cell carcinoma. The composition is particularly useful for use in the treatment of renal cell carcinoma associated with Von Hippel-Lindau disease or Birt-Hogg-Dubé syndrome. A composition comprising mithramycin or a pharmaceutically acceptable salt or solvate thereof for use as a cytotoxic agent against FLCN-null or VHL-null renal cell carcinoma cells.
    Type: Application
    Filed: February 17, 2011
    Publication date: June 13, 2013
    Applicant: Myrovlytis Technology Ventures Limited
    Inventors: Eamonn Maher, Xiaohong Lu
  • Patent number: 8461122
    Abstract: The disclosure relates to derivatives of morphine-6-glucuronide of formula (I) wherein R1 is as defined in the disclosure, or an acid addition salt thereof, as well as in hydrate or solvate form. The disclosure also relates to the preparation method thereof and to the use of same in therapeutics.
    Type: Grant
    Filed: June 8, 2011
    Date of Patent: June 11, 2013
    Assignee: Sanofi
    Inventors: Alain Dlubala, Claire Trecant, Isabelle Ripoche
  • Publication number: 20130143830
    Abstract: The present invention relates to the use of an agent to combat and reduce the irritating action of primary surfactants in compositions to be applied to the skin for care or cleansing of the face and body, characterized in that said agent is chosen from one or more salts of glycyrrhizic acid, such as monoammonium glycyrrhizinate (MAG) and dipotassium glycyrrhizinate (DPG).
    Type: Application
    Filed: January 25, 2013
    Publication date: June 6, 2013
    Applicant: GIULIANI S.P.A
    Inventor: GIULIANI S.P.A
  • Publication number: 20130143831
    Abstract: The invention provides topical pharmaceutical compositions comprising flurbiprofen, or a pharmaceutically acceptable derivative thereof, in combination with a solubilising system which comprises at least one glycol ether and at least one glycol ester. These are suitable for treating any condition associated with pain, inflammation and/or stiffness, for example sub-dermal pain in the joints or soft tissue.
    Type: Application
    Filed: June 28, 2011
    Publication date: June 6, 2013
    Applicant: EDKO PAZARLAMA TANITIM TICARET LIMITED SIRKETI
    Inventors: Koral Embil, Ray Figueroa
  • Publication number: 20130142730
    Abstract: The present invention provides organic arsenicals. Many of these compounds have potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia.
    Type: Application
    Filed: November 14, 2012
    Publication date: June 6, 2013
    Applicant: ZIOPHARM ONCOLOGY, INC.
    Inventor: ZIOPHARM Oncology, Inc.
  • Patent number: 8440634
    Abstract: The disclosure relates to compounds of formula (I): wherein R1, R2, and n are as defined in the disclosure, and addition salts solvates and hydrates thereof. The disclosure also relates to the preparation method of said compounds and to the use of the same in therapeutics.
    Type: Grant
    Filed: June 8, 2011
    Date of Patent: May 14, 2013
    Assignee: Sanofi
    Inventors: Alain Dlubala, Claire Trecant, Isabelle Ripoche
  • Publication number: 20130101632
    Abstract: Methods and formulations for improving therapeutic potential of mithramycin (MTM) or MTM analogues are disclosed. For example, in certain aspects, methods for preparing a composition containing MTM or an MTM analogue nanoparticulate formulation and uses thereof are described. Furthermore, methods for delivering MTM or MTM analogues are disclosed.
    Type: Application
    Filed: September 20, 2012
    Publication date: April 25, 2013
    Applicant: UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION
    Inventor: University of Kentucky Research Foundation
  • Patent number: 8420661
    Abstract: The present invention relates to ethynyl compounds of formula I wherein R1, R2, R2?, R3, R3?, R4, R4?, U, V, W, Y, m, and n are as defined herein and to a pharmaceutically acceptable acid addition salts, to a racemic mixtures, or to its corresponding enantiomers and/or optical isomers and/or stereoisomers thereof. Compounds of formula I are allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5).
    Type: Grant
    Filed: April 5, 2011
    Date of Patent: April 16, 2013
    Assignee: Hoffmann-la Roche Inc.
    Inventors: Luke Green, Wolfgang Guba, Georg Jaeschke, Synese Jolidon, Lothar Lindemann, Antonio Ricci, Daniel Rueher, Heinz Stadler, Eric Vieira
  • Patent number: 8394776
    Abstract: The invention provides the use of ursolic acid saponin and oleanolic acid saponin of formula (I) in preparing medicaments for increasing leucocytes and/or platelets. The invention also provides a pharmaceutical composition containing the same compound. The invention utilizes the cheap and accessible ursolic acid and oleanolic acid which are widely present in natural plants as raw materials, introduces monosaccharyls or oligosaccharyls by structural modification. It is proved by pharmacological tests that the compound of formula (I) have an activity of obviously increasing leucocytes and/or platelets.
    Type: Grant
    Filed: January 16, 2008
    Date of Patent: March 12, 2013
    Assignee: Chengdu Di'Ao Jiuhong Pharmaceutical Factor
    Inventors: Bing Guang, Junjian Liu, Guangxin Dong, Xiangyang Peng, Xiaoxia Gong, Zhen Huang, Meirong Zhou, Wei Zhan, Jufang Yan, Yu Huang, Dongguang Qin, Jianxin Ji, Bogang Li
  • Patent number: 8389697
    Abstract: The present invention relates to conjugates of therapeutically useful anthracyclines with carriers such as polyclonal and monoclonal antibodies, proteins or peptides of natural or synthetic origin; methods for their preparation, pharmaceutical composition containing them and use thereof in treating certain mammalian tumors.
    Type: Grant
    Filed: January 27, 2012
    Date of Patent: March 5, 2013
    Assignee: Genentech, Inc.
    Inventors: Italo Beria, Michele Caruso, John A. Flygare, Vittoria Lupi, Rita Perego, Paul Polakis, Andrew Polson, Matteo Salsa, Susan D. Spencer, Barbara Valsasina
  • Publication number: 20130042482
    Abstract: A skin engaging member suitable for use in a hair removal device, said skin engaging member comprising an anti-irritation agent.
    Type: Application
    Filed: August 15, 2012
    Publication date: February 21, 2013
    Inventors: Valerie Jean Bradford, Michael Joseph Kwiecien, Timothy Woodrow Coffindaffer, Karen Marie Lammers, Edward Dewey Smith, III, Jason Edward Cook, Brian Joseph Limberg
  • Patent number: 8367624
    Abstract: The present invention includes compositions and methods for the treatment of plants against pathogens, elimination of insects and to increase the shelf-life of fruits and vegetables that includes coating the plant with undiluted aloe vera gel.
    Type: Grant
    Filed: November 16, 2007
    Date of Patent: February 5, 2013
    Assignee: Coats Agril Aloe, LLC
    Inventor: Billy C. Coats
  • Patent number: 8361973
    Abstract: The present invention provides glycoside compounds, methods of preparing such compounds, pharmaceutical compositions comprising such compounds, and a method for the treatment of hyperproliferative diseases using the same.
    Type: Grant
    Filed: August 7, 2009
    Date of Patent: January 29, 2013
    Assignee: Centrose, LLC
    Inventors: Mohammed S. Shekhani, James R. Prudent, Jill Hutchinson Bollettieri
  • Publication number: 20130018009
    Abstract: The present invention relates to compositions comprising one or more anthraquinones for use in the treatment of obesity and related metabolic and liver disease. More particularly it relates to a plant extract fraction rich in anthraquinones including both anthraquinone glycosides and anthraquinone aglycones obtainable from a member of the Leguminosae family, more particularly Cassia seeds. It also relates to a method of obtaining a plant extract fraction rich in anthraquinones.
    Type: Application
    Filed: July 17, 2012
    Publication date: January 17, 2013
    Inventors: Bendong Huang, Nanming Chen, Edward Duncan Blair
  • Publication number: 20130012464
    Abstract: The present invention provides a pharmaceutically acceptable compound, a pharmaceutical composition comprising the above-mentioned pharmaceutically acceptable compound. The pharmaceutically acceptable compound provided by the present invention is a salt of a basic group-containing morphinan derivative and a carboxyl group-containing glycyrrhizinic acid and has the ability to be used to manufacture medicaments for treating and/or preventing cough, ameliorating pains, treating respiratory system diseases, treating cardiovascular diseases and treating liver diseases.
    Type: Application
    Filed: July 7, 2011
    Publication date: January 10, 2013
    Inventors: Chin-Tsai FAN, Cheng-Shun Lai, Wen-Yen Yeh, Yu-Ying Liu
  • Publication number: 20130012434
    Abstract: The present invention relates to compounds of the general formula: wherein ring A, ring B, R1, R3, Z, L1, and L2 are selected independently of each other and are as defined herein, to compositions comprising the compounds, and to methods of using the compounds as glucagon receptor antagonists and for the treatment or prevention of type 2 diabetes and conditions related thereto.
    Type: Application
    Filed: March 22, 2011
    Publication date: January 10, 2013
    Inventors: Michael K. Wong, Brian J. Lavey, Wensheng Yu, Joseph A. Kozlowski, Duanc E. DeMong, Xing Dai, Andrew W. Stamford, Michael W. Miller, Guowei Zhou, De-Yi Yang, William J. Greenlee
  • Publication number: 20130005666
    Abstract: The NF-E2-related factor 2 (Nrf2) is a key transcriptional regulator of antioxidant defense and detoxification. To directly monitor stabilization of Nrf2 we fused its Neh2 domain, responsible for the interaction with its nucleocytoplasmic regulator, Keap1, to firefly luciferase (Neh2-luciferase). It is shown herein that Neh2 domain is sufficient for recognition, ubiquitination and proteasomal degradation of Neh2-luciferase fusion protein. The novel Neh2-luc reporter system allows direct monitoring of the adaptive response to redox stress and classification of drugs based on the time-course of reporter activation. The novel reporter was used to screen a library of compounds to identify activators of Nrf2. The most robust and yet non toxic Nrf2 activators found—nordihydroguaiaretic acid, fisetin, and gedunin-induced astrocyte-dependent neuroprotection from oxidative stress via an Nrf2-dependent mechanism.
    Type: Application
    Filed: June 29, 2012
    Publication date: January 3, 2013
    Applicant: CORNELL UNIVERSITY
    Inventors: Rajiv RATAN, Irina GAZARYAN, Natalya A. SMIRNOVA
  • Patent number: 8334269
    Abstract: This invention provides compositions, methods and process of producing extracts from Xanthoceras sorbifolia. The extract comprises alkaloids, coumarins, saccharides, proteins, polysaccharides, glycosides, saponins, tannins, acid, flavonoids and others. The composition can be used for treating cancer, arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, coronary heart disease, headache, dizziness, kidney disorder, impotence and premature ejaculation; for preventing cerebral aging; for improving memory, cerebral functions; or for curing enuresis, frequent micturition, urinary incontinence, dementia, weak intelligence and Alzheimer's disease, autism, brain trauma, Parkinson's disease or other diseases caused by cerebral dysfunctions, and treating arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, coronary heart disease, headache, dizziness, kidney disorder.
    Type: Grant
    Filed: February 25, 2009
    Date of Patent: December 18, 2012
    Assignee: Pacific Arrow Limited
    Inventors: Pui-Kwong Chan, May Sung Mak, Yun Wang
  • Patent number: 8324282
    Abstract: This application provides compositions and methods useful in the treatment of certain cancers. In part, this application is based on the recognition that certain molecules that target abasic lesions or AP sites in DNA improve, augment, or potentiate the chemotherapeutic efficacy of certain anticancer agents.
    Type: Grant
    Filed: February 19, 2003
    Date of Patent: December 4, 2012
    Assignee: Case Western Reserve University
    Inventors: Stanton L. Gerson, Lili Liu
  • Patent number: 8324177
    Abstract: The invention provides saponin mixtures and compounds which are isolated from the species Acacia victoriae and methods for their use. These compounds may contain a triterpene moiety, such as acacic or oleanolic acid, to which oligosaccharides and monoterpenoid moieties are attached. The mixtures and compounds have properties related to the regulation of apoptosis and cytotoxicity of cells and exhibit potent anti-tumor effects against a variety of tumor cells.
    Type: Grant
    Filed: June 14, 2011
    Date of Patent: December 4, 2012
    Assignee: Research Development Foundation
    Inventors: Charles J. Arntzen, Mary E. Blake, Jordan U. Gutterman, Joseph J. Hoffmann, Gamini S. Jayatilake, David T. Bailey
  • Publication number: 20120295860
    Abstract: The present invention relates to a compound The instant invention relates to a compound of formulae (I A), (I B), (X A), (X B), (Y A) or (Y B), wherein R? represents and R? represents hydrogen, hydroxy, C1-C7alkoxy, C1-C8-alkanoyloxy, or R5R4N—CO—O—, where R4 and R5 independently are C1-C7alkyl or phenyl which is unsubstituted or substituted by a substitutent selected from C1-C7alkyl, C1-C7alkoxy, halogen and trifluoromethyl and where R4 additionally is hydrogen; or R4 and R5 together represent C3-C6alkylene, in free form or in form of a pharmaceutically acceptable acid addition salt. Compounds of formulae (I A), (I B), (X A), (X B), (Y A) or (Y B) inhibit DPP-IV (dipeptidyl-peptidase-IV) activity. They are therefore indicated for use as pharmaceuticals in inhibiting DPP-IV and in the treatment of conditions mediated by DPP-IV, such as non-insulin-dependent diabetes mellitus, arthritis, obesity, osteoporosis and further conditions of impaired glucose tolerance.
    Type: Application
    Filed: July 27, 2012
    Publication date: November 22, 2012
    Inventors: Ulrich Hassiepen, Matthias Kittelmann
  • Publication number: 20120270823
    Abstract: Aureolic acid derivatives, process for obtaining them and uses thereof. This invention provides a bacterial strain that produces compound belonging to the family of aureolic acids useful in the treatment of cancer or nervous system diseases.
    Type: Application
    Filed: July 14, 2010
    Publication date: October 25, 2012
    Applicant: ENTRECHEM, S.L.
    Inventors: Luz Elena Núñez Gonzáez, Beatriz García Fernández, María Pérez Solares, Alfredo Fernández Braña, Nuria Menéndez Sánchez, Javier González Sabin, Francisco Morís Varas, María del Carmen Méndez Fernández, José Antonio Salas Fernández
  • Patent number: 8293788
    Abstract: 4-(trifluoromethanesulfonyloxyphenyl)propionic acid derivatives and pharmaceutical composition containing such compounds are useful in inhibiting the chemotactic activation of neutrophils (PMN leukocytes) induced by the interaction of Interleukin-8 (IL-8) with CXCR1 and CXCR2 membrane receptors. The compounds are used for the prevention and treatment of pathologies deriving from said activation. Notably, these metabolites are devoid of cyclo-oxygenase inhibition activity and are particularly useful in the treatment of neutrophil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bullous pemphigoid, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of damages caused by ischemia and reperfusion.
    Type: Grant
    Filed: September 15, 2011
    Date of Patent: October 23, 2012
    Inventors: Marcello Allegretti, Marla Candida Cesta, Riccardo Bertini, Marco Mosca, Francesco Colotta
  • Publication number: 20120263660
    Abstract: This invention relates to the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the prevention or treatment of stress induced hair loss.
    Type: Application
    Filed: April 16, 2012
    Publication date: October 18, 2012
    Applicant: POP TEST CORTISOL LLC
    Inventors: Randice Lisa Altschul, Neil David Theise, Myron Rapkin, Rebecca O'Brien
  • Publication number: 20120237508
    Abstract: The present invention relates to HSP90 inhibitors containing fused amino pyridine core that are useful as inhibitors of HSP90 and their use in the treatment of HSP90 related diseases and disorders such as cancer, an autoimmune disease, or a neurodegenerative disease.
    Type: Application
    Filed: March 20, 2012
    Publication date: September 20, 2012
    Inventors: Xiong Cai, Changgeng Qian, Haixiao Zhai
  • Publication number: 20120231063
    Abstract: Provided is a dressing, comprising (a) a substrate layer and (b) an active layer, which is a nanofiber layer and comprises: (b1) at least one of gelatin and collagen; (b2) polyvinyl alcohol (PVA); and (b3) at least one of asiaticoside and a Centella asiatica extract. Also, a method for preparing the dressing is provided.
    Type: Application
    Filed: June 16, 2011
    Publication date: September 13, 2012
    Applicant: CHINA MEDICAL UNIVERSITY
    Inventors: Chun-Hsu YAO, Jen-Yu Yeh
  • Patent number: 8252751
    Abstract: The present invention relates to a compound The instant invention relates to a compound of formulae (I A), (I B), (X A), (X B), (Y A) or (Y B), wherein R? represents and R? represents hydrogen, hydroxy, C1-C7alkoxy, C1-C8-alkanoyloxy, or R5R4N—CO—O—, where R4 and R5 independently are C1-C7alkyl or phenyl which is unsubstituted or substituted by a substitutent selected from C1-C7alkyl, C1-C7alkoxy, halogen and trifluoromethyl and where R4 additionally is hydrogen; or R4 and R5 together represent C3-C6alkylene; in free form or in form of a pharmaceutically acceptable acid addition salt. Compounds of formulae (I A), (I B), (X A), (X B), (Y A) or (Y B) inhibit DPP-IV (dipeptidyl-peptidase-IV) activity. They are therefore indicated for use as pharmaceuticals in inhibiting DPP-IV and in the treatment of conditions mediated by DPP-IV, such as non-insulin-dependent diabetes mellitus, arthritis, obesity, osteoporosis and further conditions of impaired glucose tolerance.
    Type: Grant
    Filed: November 25, 2008
    Date of Patent: August 28, 2012
    Assignee: Novartis AG
    Inventors: Ulrich Hassiepen, Matthias Kittelmann
  • Publication number: 20120195890
    Abstract: Oligonucleotides inhibiting cellular migration, and the use of at least one inhibitor of protein expression, which inhibits the expression of TSP1 protein, or a protein, which controls the expression of TSP1 or mediates the activity of TSP1, or one inhibitor of protein activity, this inhibitor inhibiting the activity of the TSP1 protein, in particular the activity responsible for the stimulation of cell migration, or one protein which controls the expression or mediates the activity of TSP1 for the manufacture of a drug for the prevention or the treatment of primary tumors or invasive or metastatic tumors.
    Type: Application
    Filed: July 30, 2010
    Publication date: August 2, 2012
    Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Florence Cabon, Virginie Firlej, Catherine Gallou-Kabani, Natalia Catherine Prevarskaya
  • Publication number: 20120196751
    Abstract: Provided is a formulation comprising (a) a preparation comprising one or more anthraquinone derivatives having activity against plant pests and (b) a lignin. Also provided is a method for obtaining the formulation and for using the formulation to modulate phytopathogenic, fungal and/or bacterial infection and/or plant pest infestation.
    Type: Application
    Filed: February 2, 2012
    Publication date: August 2, 2012
    Applicant: MARRONE BIO INNOVATIONS, INC.
    Inventors: James Namnath, Hai Su
  • Publication number: 20120189684
    Abstract: This invention relates to skincare compositions, in particular compositions effective in the treatment of acne vulgaris, and to methods of treatment of the skin that involve the application of such compositions, wherein the compositions comprise salicylic acid or a salt thereof in combination with at 2 actives selected from the group consisting of lactic acid or a salt thereof; glycyrrhizinic acid or a salt or derivative thereof; bisabolol; cetylhydroxyproline palmitamide; allantoin; niacinamide; and epilobium angustifolium extract.
    Type: Application
    Filed: July 19, 2010
    Publication date: July 26, 2012
    Applicant: Reckitt Benckiser Healthcare International Limited
    Inventors: Carolyn Buckley, Stuart Jackson, Neil Kilcullen, Diane Marie Pavis
  • Publication number: 20120189678
    Abstract: A liposome comprising a phospholipid, a hydrophobic active comprising a carboxylate group, and a component selected from a group consisting of: a hydrophilic adjuvant comprising a positively charged group, a complex of said hydrophobic active with said hydrophilic adjuvant, and combinations thereof. An aqueous liposome dispersion comprising the liposome, and a personal care composition comprising the liposome. A process of preparing the liposome, comprising the steps of: forming a premix by dissolving a phospholipid, a hydrophobic active comprising a carboxylate group in an organic solvent; evaporating off said organic solvent from the premix to form a phospholipid film; and hydrating said lipid film with a hydration medium comprising a hydrophilic adjuvant comprising a positively charged group and homogenize the medium to form an aqueous liposome dispersion.
    Type: Application
    Filed: January 25, 2012
    Publication date: July 26, 2012
    Inventors: Chengwu LI, Naohisa Yoshimi, Xincheng Hu, Shuang Li, Yunhua Gao
  • Patent number: 8227425
    Abstract: The invention provides a new class of compounds exhibiting an inhibitory effect on neuraminidase (NA), hemagglutinin (HA) and structural M2 protein bearing viruses. These compounds are also useful as inhibitors of the replication factors of hepatitis virus type C (HVC). The invention also describes pharmaceutical compositions containing the compounds of the invention either alone or in combination admixed with a suitable and pharmaceutically acceptable carrier.
    Type: Grant
    Filed: January 22, 2008
    Date of Patent: July 24, 2012
    Assignee: Therapicon Srl
    Inventors: Paolo Alberto Veronesi, Pablo Eduardo Andres Rodriguez, Emanuela Peschechera, Susanna Lucia Veronesi
  • Publication number: 20120165279
    Abstract: A pharmaceutical composition for preventing or treating hepatitis C is provided, including oleanolic acid derivatives as an active ingredient and a pharmaceutically acceptable carrier. A method for preventing or treating hepatitis C in a subject in need thereof is also provided by administering the subject the pharmaceutical composition given above.
    Type: Application
    Filed: October 26, 2011
    Publication date: June 28, 2012
    Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Lain-Tze Lee, Shau-Feng Chang, Zong-Keng Kuo, Hui-Ping Tsai
  • Patent number: 8178500
    Abstract: Stabilized mixtures of pesticides are disclosed.
    Type: Grant
    Filed: August 25, 2009
    Date of Patent: May 15, 2012
    Assignee: Dow AgroSciences LLC
    Inventors: Kuide Qin, Raymond E. Boucher, Jr., Dennis G. Wujek
  • Patent number: 8173610
    Abstract: The present invention relates to novel derivatives of epirubicin, pharmaceutical composition comprising these derivatives, and uses of epirubicin and its derivative for treating HCV.
    Type: Grant
    Filed: November 14, 2006
    Date of Patent: May 8, 2012
    Assignees: Instytut Biochemii I Biofizyki, Institut National de Las Sante Et de la Recherche Medicale (Inserm), Instytut Medycyny Doswiadczalnej I Kliniczne
    Inventors: Tadeusz Kulikowski, Maria Bretner, Andzelika Najda, Lucyna Cova, Christian Trepo, Ramamurthy Narayan, Andrzej Piasek, Andrzej Lipniacki, Wlodzimierz Zagorski-Ostoja
  • Publication number: 20120109051
    Abstract: Disclosed are various embodiments of intra-oral taste modification devices, both erodible and non-erodible, and methods for using the devices, and methods and kits for making the devices, for controlling food intake by reducing the desire to eat highly sweetened foods and refined carbohydrates.
    Type: Application
    Filed: May 26, 2011
    Publication date: May 3, 2012
    Inventor: Robert Collins Harrell
  • Publication number: 20120100223
    Abstract: Lipid compositions comprising nuts, seeds, oils, legumes, fruits, grains, and dairy useful in specified amounts as dietary supplements and diet plans designed around and including the aforementioned for the prophylaxis and treatment of numerous diseases are disclosed. The compositions include omega-6 and omega-3 fatty acids where the ratio of the omega-6 to the omega-3 fatty acids and their amounts are controlled based on one or more factors including age of the subject, sex of the subject, diet of the subject, the body weight of the subject, medical conditions of the subject, and climate of the subject's living area.
    Type: Application
    Filed: December 20, 2011
    Publication date: April 26, 2012
    Applicant: ASHA NUTRITION SCIENCES, INC.
    Inventor: Urvashi BHAGAT
  • Patent number: 8158591
    Abstract: A 13-deoxy anthracycline and a taxane can be administered to a patient simultaneously, separately, sequentially, or consecutively to produce a therapeutic anticancer effect with reduced toxicity and side effect profile, compared to the administration of equieffective amounts of either compound alone. A composition or preparation of a 13-deoxy anthracyclines and a taxane for producing a potent anticancer therapeutic effect is also provided.
    Type: Grant
    Filed: August 17, 2010
    Date of Patent: April 17, 2012
    Assignee: Gem Pharmaceuticals, LLC
    Inventors: Richard D. Olson, Gerald M. Walsh
  • Publication number: 20120071431
    Abstract: Extracts of radix platycodin are used to inhibit angiogenesis, particularly angiogenesis that is associated with disease conditions other than obesity or cancer.
    Type: Application
    Filed: March 28, 2011
    Publication date: March 22, 2012
    Inventors: Frank L. Greenway, Zhijun Liu
  • Publication number: 20120071704
    Abstract: The invention provides methods of identifying and making compounds that inhibit the interaction between MUC1 and either or both of HSP70 and HSP90. Also embraced by the invention are in vivo and in vitro methods of inhibiting such an interaction.
    Type: Application
    Filed: September 13, 2011
    Publication date: March 22, 2012
    Inventor: Donald W. KUFE